These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 6181125)

  • 1. Study of serotonin in neuropsychiatric disorders.
    Van Woert MH; Magnussen I; Lowe YH; Hwang EC
    J Histochem Cytochem; 1982 Aug; 30(8):824-7. PubMed ID: 6181125
    [No Abstract]   [Full Text] [Related]  

  • 2. Serotonin and myoclonus.
    Van Woert MH; Jutkowitz R; Rosenbaum D; Bowers MB
    Monogr Neural Sci; 1976; 3():71-80. PubMed ID: 790170
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and metabolic observations on the treatment of myoclonus with L-5-HTP and carbidopa.
    Thal L; Sharpless N; Wolfson L; Engel J; Katzman R
    Trans Am Neurol Assoc; 1976; 101():48-52. PubMed ID: 1088459
    [No Abstract]   [Full Text] [Related]  

  • 4. Therapy of intention myoclonus with L-5-hydroxytryptophan and a peripheral decarboxylase inhibitor, MK 486.
    Van Woert MH; Sethy VH
    Neurology; 1975 Feb; 25(2):135-40. PubMed ID: 1078720
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Serotoninergic conception of myoclonic syndromes. (Review)].
    Levin SL
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1979; 79(6):797-803. PubMed ID: 224629
    [No Abstract]   [Full Text] [Related]  

  • 6. Long-term therapy of myoclonus and other neurologic disorders with L-5-hydroxytryptophan and carbidopa.
    Van Woert MH; Rosenbaum D; Howieson J; Bowers MB
    N Engl J Med; 1977 Jan; 296(2):70-5. PubMed ID: 401457
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HVA and 5HIAA CSF measurements and 5HTP trials in some patients with involuntary movements.
    Guilleminault C; Tharp BR; Cousin D
    J Neurol Sci; 1973 Apr; 18(4):435-41. PubMed ID: 4540626
    [No Abstract]   [Full Text] [Related]  

  • 8. Effects of L-5-hydroxytryptophan on monoamine and amino acids turnover in the Lesch-Nyhan syndrome.
    Castells S; Chakrabarti C; Winsberg BG; Hurwic M; Perel JM; Nyhan WL
    J Autism Dev Disord; 1979 Mar; 9(1):95-103. PubMed ID: 312282
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The indoleamine hypothesis of depression: an overview and pilot study.
    Zarcone VP; Berger PA; Brodie KH; Sack R; Barchas JD
    Dis Nerv Syst; 1977 Aug; 38(8):646-53. PubMed ID: 328245
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel neurodevelopmental syndrome responsive to 5-hydroxytryptophan and carbidopa.
    Ramaekers VT; Senderek J; Häusler M; Häring M; Abeling N; Zerres K; Bergmann C; Heimann G; Blau N
    Mol Genet Metab; 2001 Jun; 73(2):179-87. PubMed ID: 11386854
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fluoxetine in the treatment of intention myoclonus.
    Van Woert MH; Magnussen I; Rosenbaum D; Chung E
    Clin Neuropharmacol; 1983 Mar; 6(1):49-54. PubMed ID: 6189599
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biochemistry and therapeutics of posthypoxic myoclonus.
    Van Woert MH; Rosenbaum D; Chung EY
    Adv Neurol; 1986; 43():171-81. PubMed ID: 2418644
    [No Abstract]   [Full Text] [Related]  

  • 13. [Central metabolism of dopamine and serotonin. I. Determination of cerebrospinal fluid levels of HVA and 5-HIAA by the probenecid test (modified)].
    Carrieri P; Campanella G; Mandarini A; Orefice G; Buscaino GA
    Acta Neurol (Napoli); 1976; 31(5):558-64. PubMed ID: 1015382
    [No Abstract]   [Full Text] [Related]  

  • 14. Effect of l-5-hydroxytryptophan on brain monoamine metabolism and evaluation of its clinical effect in depressed patients.
    Takahashi S; Kondo H; Kato N
    J Psychiatr Res; 1975 Nov; 12(3):177-87. PubMed ID: 1081591
    [No Abstract]   [Full Text] [Related]  

  • 15. Beneficial effects of serotonin precursors in postanoxic action myoclonus.
    De Léan J; Richardson JC; Hornykiewicz O
    Neurology; 1976 Sep; 26(9):863-8. PubMed ID: 1084968
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical, biochemical, and physiological features distinguishing myoclonus responsive to 5-hydroxytryptophan, tryptophan with a monoamine oxidase inhibitor, and clonazepam.
    Chadwick D; Hallett M; Harris R; Jenner P; Reynolds EH; Marsden CD
    Brain; 1977 Sep; 100(3):455-87. PubMed ID: 412560
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serotoninergic dysfunction in the 47, XYY syndrome.
    Bioulac B; Benezech M; Renaud B; Noel B; Roche D
    Biol Psychiatry; 1980 Dec; 15(6):917-23. PubMed ID: 6161648
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 5-hydroxytryptophan (5-HTP) in Down's syndrome.
    Partington MW; MacDonald MR
    Dev Med Child Neurol; 1971 Jun; 13(3):362-72. PubMed ID: 4255254
    [No Abstract]   [Full Text] [Related]  

  • 19. Serotonergic mechanisms and extrapyramidal function in man.
    Chase TN
    Adv Neurol; 1974; 5():31-9. PubMed ID: 4280243
    [No Abstract]   [Full Text] [Related]  

  • 20. Kinetics of l-5-hydroxytryptophan in healthy subjects.
    Westenberg HG; Gerritsen TW; Meijer BA; van Praag HM
    Psychiatry Res; 1982 Dec; 7(3):373-85. PubMed ID: 6187038
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.